Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Immunology
Factor de Impacto: 1.352 Factor de Impacto de 5 años: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN En Línea: 2162-6472

Volumes:
Volumen 40, 2020 Volumen 39, 2019 Volumen 38, 2018 Volumen 37, 2017 Volumen 36, 2016 Volumen 35, 2015 Volumen 34, 2014 Volumen 33, 2013 Volumen 32, 2012 Volumen 31, 2011 Volumen 30, 2010 Volumen 29, 2009 Volumen 28, 2008 Volumen 27, 2007 Volumen 26, 2006 Volumen 25, 2005 Volumen 24, 2004 Volumen 23, 2003 Volumen 22, 2002 Volumen 21, 2001 Volumen 20, 2000 Volumen 19, 1999 Volumen 18, 1998 Volumen 17, 1997 Volumen 16, 1996 Volumen 15, 1995 Volumen 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.2018027460
pages 433-451

IL-7 and Its Beneficial Role in Sepsis-Induced T Lymphocyte Dysfunction

Charles de Roquetaillade
EA7426 "Pathophysiology of Injury-Induced Immunosuppression (PI3)", Université Claude Bernard Lyon 1, Lyon, France
Guillaume Monneret
EA7426 "Pathophysiology of Injury-Induced Immunosuppression (PI3)", Université Claude Bernard Lyon 1, Lyon, France; Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France
Morgane Gossez
EA7426 "Pathophysiology of Injury-Induced Immunosuppression (PI3)", Université Claude Bernard Lyon 1, Lyon, France; Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France
Fabienne Venet
EA7426 "Pathophysiology of Injury-Induced Immunosuppression (PI3)", Université Claude Bernard Lyon 1, Lyon, France; Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France

SINOPSIS

Sepsis, defined as life-threatening organ dysfunction caused by dysregulated host response to infection, has recently been acknowledged as a worldwide health priority. Sepsis remains the leading cause of mortality in intensive care units and accounts for 6 million deaths every year. Few therapeutic options targeting host immune response in sepsis have demonstrated their efficacy so far. Increasing evidence suggests that a profound immune suppression develops following sepsis, affecting innate and adaptive immune response, of which intensity and duration is associated with increased risk of death and nosocomial infection. Immunostimulant treatments are thus now evaluated in sepsis, and recombinant human IL-7 (rhIL-7) represents a promising candidate. rhIL-7 has been evaluated in several clinical trials in patients with altered lymphocytic responses (HIV infection, hematopoietic stem cell transplantation, and cancer). Recent studies in animal models and in patients' samples ex vivo demonstrated its efficacy in improving sepsis-induced T cell alterations. Finally, the first clinical trial evaluating rhIL-7 in septic shock patients has just been published. This review will discuss the use of rhIL-7 to treat sepsis-induced T cell dysfunction by introducing the pathophysiology of sepsis and sepsis-related lymphocyte alterations before focusing on rhIL-7 and its potential use of as a therapeutic intervention in patients.